Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson's disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer's disease. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida. Show more
Location: 100 SE 2nd Street, Miami, FL, 33131, United States | Website: https://telomirpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
38.09M
52 Wk Range
$1.12 - $8.40
Previous Close
$1.18
Open
$1.18
Volume
1,382,277
Day Range
$1.18 - $1.34
Enterprise Value
38.51M
Cash
754.3K
Avg Qtr Burn
-791.9K
Insider Ownership
31.50%
Institutional Own.
8.73%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|